期刊
GERIATRICS & GERONTOLOGY INTERNATIONAL
卷 22, 期 4, 页码 298-304出版社
WILEY
DOI: 10.1111/ggi.14363
关键词
heart failure; left ventricular diastolic function; sodium-glucose cotransporter 2 inhibitors
资金
- Kotobuki Pharmaceutical
In this randomized controlled study focusing on patients with type 2 diabetes and heart failure with preserved ejection fraction, 24-week treatment with ipragliflozin did not improve left ventricular diastolic function compared to conventional treatment. In subgroup analysis, ipragliflozin treatment led to a decrease in left ventricular mass index in participants aged 70 and above.
Aim We carried out a randomized controlled trial using ipragliflozin. We analyzed changes in diastolic function using echocardiography in patients with type 2 diabetes and heart failure with preserved ejection fraction. Methods We carried out an open-label, multicenter, randomized, two-arm interventional trial. A total of eligible 68 participants were randomly assigned into two groups (ipragliflozin group n = 36; conventional treatment group n = 32). Primary end-points were the change in E/e' and e'. Secondary end-points were other parameters of echocardiography, plasma NT-proBNP level, New York Heart Association class, hemoglobin A1c and blood pressure. Results After 24 weeks of follow up, E/e' decreased in both groups (ipragliflozin: 11.0 vs 10.4; conventional treatment 10.5 vs 10.1; multivariate-adjusted P = 0.95). There were no significant differences in the amount of change in E/e', e', echocardiography parameters, plasma NT-proBNP level, New York Heart Association class, hemoglobin A1c and blood pressure between the two groups. In the subgroup analysis, ipragliflozin treatment decreased in left ventricular mass index in patients aged >= 70 years and also decreased in NT-proBNP levels in patients with baseline NT-proBNP >= 400 pg/mL. Conclusions In this randomized controlled study carried out in patients with type 2 diabetes and heart failure with preserved ejection fraction, 24-week ipragliflozin treatment did not improve left ventricular diastolic function compared with conventional treatment. As the subgroup, ipragliflozin treatment decreased in left ventricular mass index in participants aged >= 70 years. Geriatr Gerontol Int 2022; center dot center dot: center dot center dot-center dot center dot.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据